Speakers

Michael Dowling is one of healthcare’s most influential voices, taking a stand on societal issues such as gun violence and immigration that many health system CEOs shy away from. As president and CEO of Northwell Health, he leads a clinical, academic and research enterprise with a workforce of more than 85,000 and annual revenue of $16.5 billion. Northwell is the largest health care provider and private employer in New York State, caring for more than two million people annually through a vast network of more than 890 outpatient facilities, including 220 primary care practices, 52 urgent care centers, home care, rehabilitation and end-of-life programs, and 21 hospitals.

Northwell also pursues pioneering research at the Feinstein Institutes for Medical Research and a visionary approach to medical education highlighted by the Zucker School of Medicine, the Hofstra Northwell School of Nursing and Physician Assistant Studies, and one of the nation’s largest medical residency and fellowship programs.

Mr. Dowling’s leadership has been invaluable to Northwell’s consistent expansion and prominence. In 2020, he successfully navigated the health system through the first COVID-19 epicenter in the US, detailing his experiences in Leading Through a Pandemic: The Inside Story of Humanity, Innovation, and Lessons Learned During the COVID-19 Crisis. Overall, Northwell has treated more than 350,000 COVID patients, and the health system utilized a strong innovative culture to expand hospital bed capacity (adding 2,000 beds in two weeks), 3D-print nasal swabs for COVID testing, convert bi-level positive airway pressure (BiPAP) machines into mechanical ventilators and take advantage of its large, integrated health system to “load balance” and transport 810 patients from overrun hospitals to those that had bed capacity. Northwell also kept employees safe, investing in critical personal protective equipment to help those working the front lines, one of whom—Sandra Lindsay—was the first person in the US to receive the historic COVID vaccine in December 2020.

Prior to becoming president and CEO in 2002, Mr. Dowling was the health system’s executive vice president and chief operating officer. Before joining Northwell Health in 1995, he was a senior vice president at Empire Blue Cross/Blue Shield. Mr. Dowling served in New York State government for 12 years, including seven years as state director of Health, Education and Human Services and deputy secretary to the governor. He was also commissioner of the New York State Department of Social Services.

Before his public service career, Mr. Dowling was a professor of social policy and assistant dean at the Fordham University Graduate School of Social Services, and director of the Fordham campus in Westchester County.

Mr. Dowling has been honored with many awards over the years. In 2020, he received the Presidential Distinguished Service Award for the Irish Abroad, which recognizes individuals for their contributions to Ireland and to Irish communities abroad, presented by the President of Ireland. He has received an honorary fellowship of the Royal College of Physicians of Ireland and is a board member of the Foreign Policy Association. In 2017, he was selected as the Grand Marshal of the St. Patrick’s Day Parade in New York City; received the Presidential Distinguished Service Award for Irish Abroad and was inducted to the Irish America Hall of Fame. He also has received the 2012 B’nai B’rith National Healthcare Award, the Ellis Island Medal of Honor, the 2011 Gail L. Warden Leadership Excellence Award from the National Center for Healthcare Leadership and the Healthcare Information and Management Systems Society. In 2020, Mr. Dowling received the Deming Cup from the Columbia School of Business.

In 2011, Modern Healthcare magazine awarded Mr. Dowling with the CEO Information Technology Award. He also was ranked first in Modern Healthcare’s 100 Most Influential People in Healthcare list in 2022, a list on which he has appeared 16 times.

Additional awards include the National Human Relations Award from the American Jewish Committee, the Distinguished Public Service Award from the State University of New York’s Nelson A. Rockefeller College of Public Affairs and Policy, an Outstanding Public Service Award from the Mental Health Association of New York State, an Outstanding Public Service Award from the Mental Health Association of Nassau County, the Alfred E. Smith Award from the American Society for Public Administration, the Gold Medal from the American Irish Historical Society and the Foreign Policy Association Medal, which is the highest honor bestowed by the organization. He was also ranked No. 44 among large company CEOs in the US and was the nation’s top-ranking health care/hospital CEO on Glassdoor’s Top CEOs in 2019 list.

Mr. Dowling is past chair of the Healthcare Institute and the current chair of the Institute for Healthcare Improvement (IHI). He is a member of the Institute of Medicine of the National Academies of Sciences and the North American Board of the Smurfit School of Business at University College, Dublin, Ireland. He also serves as a board member of the Long Island Association. He is past chair and a current board member of the National Center for Healthcare Leadership (NCHL), the Greater New York Hospital Association (GNYHA), the Healthcare Association of New York State (HANYS) and the League of Voluntary Hospitals of New York. Mr. Dowling was an instructor at the Center for Continuing Professional Education at the Harvard School of Public Health.

Mr. Dowling grew up in Limerick, Ireland. He earned his undergraduate degree from University College Cork (UCC), Ireland, and his master’s degree from Fordham University. He also has honorary doctorates from Queen’s University Belfast, University College Dublin, Hofstra University, Dowling College and Fordham University.

Kevin J. Tracey, is President and CEO and the Karches Family Distinguished Chair in Medical Research at The Feinstein Institutes for Medical Research; Professor of Neurosurgery and Molecular Medicine at the Zucker School of Medicine at Hofstra-Northwell; and Executive Vice President, Research, at Northwell Health, in New York. A leader in the scientific fields of inflammation and bioelectronic medicine, his contributions include discovery and molecular mapping neural circuits controlling immunity and identifying the therapeutic action of monoclonal anti-TNF antibodies.

Professor Tracey received his B.S. (Chemistry, summa cum laude, Phi Beta Kappa) from Boston College in 1979, and his M.D. from Boston University in 1983.  He trained in neurosurgery from 1983 to 1992 at the New York Hospital-Cornell University Medical Center and was a guest investigator at the Rockefeller University before moving in 1992 to The Feinstein Institutes.

An inventor with more than 75 United States patents, author of more than 400 scientific publications, he cofounded the Global Sepsis Alliance, a non-profit organization supporting the efforts of >1 million sepsis caregivers in more than 70 countries. His honors and awards include a Doctorates honoris causa from the Karolinska Institute, Stockholm, Sweden, the University of Fribourg, Switzerland and Hofstra University, New York; the Boston University Distinguished Alumni Award; Fellow of the AIMBE Class (2020), the Harvey Society lecture, New York; and lectureships from Harvard, Yale, Rockefeller University, the NIH, and elsewhere. His memberships include the American Society of Clinical Investigation (2001), the American Association of Physicians (2009), the Long Island Technology Hall of Fame (2012), Alpha Omega Alpha (2014), the American Association for the Advancement of Science (2014), and the American Institute for Medical and Biological Engineering (2020). Professor Tracey is author of Fatal Sequence (Dana Press), and delivers lectures nationally and internationally on inflammation, sepsis, the neuroscience of immunity, and bioelectronic medicine.

Bertha Coombs is a reporter for CNBC, covering financial markets, business news stories and health care throughout the business day. She is based at the Nasdaq Marketsite in Times Square.

Her health care coverage at CNBC has ranged from covering the implementation of the Affordable Care Act and the failed launch of the Obamacare health insurance exchanges, to how cancer researchers are using IBM’s Watson to improve cancer care, and how doctors are using mobile technology to treat patients in their own homes. She also covered the devastation of Hurricane Katrina in New Orleans, the impact of the financial crisis of 2008, and reported on the oil markets from the floor of the New York Mercantile exchange.

Before joining CNBC, Coombs was a reporter and anchor for the pioneering online business network, Yahoo Finance Vision, and served as a freelance reporter for the former CNNfn financial network. Prior, she served as a reporter for ABC News One, and a substitute anchor for “World News Now” and “World News This Morning.”

She began her career in general news, with previous reporting and anchoring positions at WABC-TV in New York, WPLG-TV in Miami and WFSB-TV in Hartford, Connecticut.

Coombs is a graduate of Yale University and was awarded the Leo Beranek Reporter Training Fellowship at WCVB-TV in Boston. Born in Havana, Cuba, she speaks fluent Spanish.

Dr. Geoffrey Ling is presently co-founder and CEO of On Demand Pharmaceuticals. Clinically, he is a professor of neurology at both Johns Hopkins University and the Uniformed Services University of the Health Sciences, and an attending neuro critical care physician at Johns Hopkins Hospital.  He serves as the Chair of the Veterans Administration’s National Research Advisory Council.

Dr. Ling is a retired U.S. Army colonel after 21 years on active duty.  He served with the 452^nd CSH in OEF (2003) and 86^th CSH and 10^th CSH in OIF (2005).   Also, COL Ling has had four in-theater missions as a member of the Joint Chiefs of Staff “Gray Team” to assess traumatic brain injury (TBI) care in the combat theater (2009, 2011).  The 10th CSH named him their first “Physician of the Month.”  Dr. Ling was also a “requested by name” consultant to Congresswoman Gabby Gifford’s trauma team following her tragic attack.

He was the Founding Director of the Biological Technologies Office at the Defense Advanced Research Projects Agency (DARPA), where he was a program manager and Deputy Director of the Defense Sciences Office.  He served as the Assistant Director for Medical Innovation in President Obama’s White House Office of Science, Technology and Policy (OSTP).  His BA cum laude is from Washington University in St. Louis, MD from Georgetown University (elected to AOA) and his PhD in neuropharmacology is from Cornell University.  He completed his neurology residency at Walter Reed Army Medical Center, neuro critical care fellowship at Johns Hopkins and research fellowship in neuropharmacology at the Memorial Sloan Kettering Cancer Center.

He is board certified in both neurology and neuro critical care.  He has published more than 200 peer-reviewed articles and book chapters.

Tyler Mathisen co-anchors CNBC’s “Power Lunch,” one of the network’s longest running program franchises. He is also Vice President, Events Strategy for CNBC, working closely with the network’s events team to grow the rapidly expanding business.

Previously, Mathisen was co-anchor of “Nightly Business Report,” an award-winning evening business news program produced by CNBC for U.S. public television. In 2014, NBR was named best radio/TV show by the Society of American Business Editors and Writers (SABEW). Since joining CNBC in 1997, Mathisen has held a number of positions including managing editor of CNBC Business News, responsible for directing the network’s daily content and coverage. He was also co-anchor of CNBC’s “Closing Bell.”

Mathisen has reported one-hour documentaries for the network including “Best Buy: The Big Box Fights Back,” “Supermarkets Inc: Inside a $500 Billion Money Machine” and “Death: It’s a Living.” Mathisen was also host of the CNBC series “How I Made My Millions.”

Prior to CNBC, Mathisen spent 15 years as a writer, senior editor and top editor for Money magazine. Among other duties, he supervised the magazine’s mutual funds coverage, its annual investment forecast issue and its expansion into electronic journalism, for which it won the first-ever National Magazine Award for New Media in 1997.

In 1993, Mathisen won the American University-Investment Company Institute Award for Personal Finance Journalism for a televised series on “Caring for Aging Parents,” which aired on ABC’s “Good Morning America.” Mathisen served as money editor of “GMA” from 1991 to 1997. He also won an Emmy Award for a report on the 1987 stock market crash that aired on New York’s WCBS-TV.

A native of Arlington,Va., Mathisen graduated with distinction from the University of Virginia.

Adam M. Koppel rejoined Bain Capital in 2016 as Managing Director of Bain Capital Life Sciences. He initially joined Bain Capital Public Equity in 2003 where he worked as a leader within the healthcare sector until 2014. From 2014 to 2016, Dr. Koppel was EVP of Corporate Development and Chief Strategy Officer at Biogen. He sits on the Board of Directors of Aptinyx (NASD: APTX), Cerevel Therapeutics, Dicerna Pharmaceuticals (NASD: DRNA), Foghorn Therapeutics, Solid Biosciences (NASD: SLDB) and ViaCyte.

Prior to initially joining Bain Capital in 2003, Dr. Koppel was an Associate Principal at McKinsey and Co in New Jersey where he served a variety of healthcare companies.

Dr. Koppel sits on the Newton-Wellesley Hospital Board of Trustees, the Boston Museum of Science Board of Trustees, the Partners Healthcare Innovation Advisory Board, and the Society for Neuroscience Investment Committee. He previously sat on the Board of Temple Beth Elohim in Wellesley MA, from 2014-2017.

Dr. Koppel received an MD and PhD in Neuroscience from the University of Pennsylvania School of Medicine. He also received an MBA from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. He graduated magna cum laude from Harvard University with an AB and AM in History and Science.

Bruce D. Broussard, President and CEO, joined Humana in 2011. Under his leadership, Humana has created an integrated care delivery model centered on improving health outcomes, driving lower costs, enhancing quality, and providing a simple and personalized member experience. With its holistic approach, Humana is dedicated to improving the health of the communities it serves by making it easy for people to achieve their best health.

Bruce brings to Humana a wide range of executive leadership experience in publicly traded and private organizations within a variety of healthcare sectors, including oncology, pharmaceuticals, assisted living/senior housing, home care, physician practice management, surgical centers and dental networks.

Prior to joining Humana, Bruce was Chief Executive Officer of McKesson Specialty/US Oncology, Inc. US Oncology was purchased by McKesson in December 2010. At US Oncology, Bruce served in a number of senior executive roles, including Chief Financial Officer, President, Chief Executive Officer and Chairman of the Board.

Bruce plays a leadership role in key business advocacy organizations such as The Business Council and the American Heart Association CEO Roundtable. He is also a member of the Board of Directors of KeyCorp and the World Economic Forum Health Governors Board.

Christine Guo is a healthcare investor at Wells Fargo Strategic Capital (“WFSC”), the venture capital and private equity arm for Wells Fargo. Wells Fargo Strategic Capital’s healthcare division invests across all sub-sectors of healthcare, including healthcare services, healthcare technology, medical devices, and life sciences.

Christine started her career in financial services at Goldman Sachs and Co’s Healthcare Investment Banking Group and Private Equity Group. She then transitioned to healthcare investing at New Enterprise Associates (NEA), where she focused on healthcare services and digital health investing. Christine then gained operating experience by joining her former digital health portfolio company, Collective Health.

Christine has a MBA from Harvard Business School and a BS and BA from University of Pennsylvania.

Dan Wattendorf, director of Innovative Technology Solutions, leads efforts to identify and create biotechnology platforms that result in new options for global health and oversees the foundation’s strategy to develop and implement new biomarkers, diagnostic tests, and diagnostic services for the developing world.

Prior to joining the foundation in 2016, Dan was program manager at the Defense Advanced Research Projects Agency (DARPA), where he initiated and lead programs in diagnostics, mammalian cell synthetic biology, RNA vaccines, rapid discovery of monoclonal antibodies, immunoprophylaxis by gene transfer, and engineered red blood cells.

Previously, he served as director, Air Force Medical Genetics Center, director of the cancer genetics center at the Walter Reed National Military Medical Center, and was a clinician in the Cancer Genetics Branch, National Cancer Institute, NIH.

Dan holds a B.S. in microbiology from Cornell University and an M.D. with distinction from George Washington University. He completed a residency in family medicine at the National Capital Consortium; a residency in clinical genetics at the National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH); a fellowship in clinical cytogenetics at Georgetown University; and a fellowship in health policy from the Office of the Director, NHGRI, NIH.

He has been a member of the Secretary of Veterans Affairs Genomic Medicine Program Advisory Committee and the Institute of Medicine’s Roundtable on Translating Genomic-Based Research for Health.

Dean Kamen is an inventor, an entrepreneur, and a tireless advocate for science and technology. His roles as inventor and advocate are intertwined—his own passion for technology and its practical uses has driven his personal determination to spread the word about technology’s virtues and by so doing to change the culture of the United States.

As an inventor, he holds more than 440 U.S. and foreign patents, many of them for innovative medical devices that have expanded the frontiers of health care worldwide. While still a college undergraduate, he invented the first wearable infusion pump, which rapidly gained acceptance from such diverse medical specialties as oncology, neonatology, and endocrinology. In 1976, he founded his first medical device company, AutoSyringe, Inc., to manufacture and market the pumps. Then, working with leading diabetes researchers, Dean pioneered the design and adoption of the first portable insulin pump. It was quickly demonstrated that using a pump could much more effectively control patients’ blood glucose levels. . At age 30, he sold AutoSyringe to Baxter Healthcare Corporation.

Following the sale of Auto Syringe, Inc., he founded DEKA Research & Development Corporation to develop internally generated inventions as well as to provide research and development for major corporate clients. Kamen led DEKA’s development of the HomeChoiceTM peritoneal dialysis system for Baxter International Inc. The HomeChoiceTM system allows patients to be dialyzed in the privacy and comfort of their home and quickly became the worldwide market leader. Kamen also led the development of technology to improve slide preparation for the CYTYC (now Hologic Inc.) ThinPrep® Pap Test. Kamen-led DEKA teams have also developed critical components of the UVARTM XTSTM System, an extracorporeal photophereisis device marketed by Therakos, a unit of Johnson & Johnson, for treatment of T-Cell lymphoma. An advanced prosthetic arm in development for DARPA should advance the quality of life for returning injured soldiers. Other notable developments include the HydroflexTM surgical irrigation pump for C.R. Bard, the CrownTM stent, an improvement to the original Palmaz-Schatz stent, for Johnson & Johnson, the iBOTTM mobility device, and the Segway® Human Transporter.

Kamen has received many awards for his efforts. Notably, Kamen was awarded the National Medal of Technology in 2000. Presented by President Clinton, this award was in recognition for inventions that have advanced medical care worldwide, and for innovative and imaginative leadership in awakening America to the excitement of science and technology. Kamen was elected a member of the National Academy of Engineering in 1997. He was awarded the Lemelson-MIT Prize in 2002, and was inducted into the National Inventors Hall of Fame in May 2005. He is a Fellow of the American Institute for Medical & Biological Engineering, as well as many other national and international engineering organizations.

In 2010, Dean hosted the Planet Green television series Dean of Invention. In addition to DEKA, one of Dean’s proudest accomplishments is founding FIRST® (For Inspiration and Recognition of Science and Technology), an organization dedicated to motivating the next generation to understand, use and enjoy science and technology. Founded in 1989, this year FIRST® will serve more than 1,000,000 young people, ages 6 to 18, in more than 86 countries around the globe. Last year, high-school-aged participants were eligible to apply for more than $50 million in scholarships from over 200 leading colleges, universities, and corporations.

Emily Kagan Trenchard is the Vice President of Digital & Innovations Strategy for Northwell Health. Adept at serving as the point of translation between doctors, developers and designers, Emily leads key areas of the business including digital patient experience strategy, use research and analytics, digital product development, and user experience design. She also serves as an advisor to Northwell’s ventures division and the IT Innovation Center, helping identify and develop new technologies.

For over a decade Emily has lead teams in designing and implementing the large-scale applications necessary to connect patients to care, and to keep businesses competitive in a time of radical change. She began her career at the Cardiovascular Research Foundation, developing content and digital engagement tools for women’s heart health. Emily then joined Lenox Hill Hospital as their head of Web Systems, where she spearheaded the development of many consumer health platforms, including the first-ever implementation of the ZocDoc scheduling platform for a hospital. Once Lenox Hill Hospital joined the Northwell family, Emily was tapped to be the system’s Director of Web Technology. In this role she helped start the user experience practice, lead a replatforming of the enterprise content management system, championed the use of open source software, built up the in-house application development team, and lead the move to agile processes.
Emily received her undergraduate education in bio-behavioral science from UC Berkeley, and holds a master’s degree in science writing and communication from MIT. Her executive training was at the Yale School of Management. Emily is a nationally recognized poet, essayist and speaker exploring the ways we can remix the human in healthcare.

Emmanuel Fombu, MD, MBA, is an Ivy League educated physician, author, speaker and healthcare executive turned Silicon Valley entrepreneur. He is a medical futurist, an advocate for value-based healthcare and the 2017 winner of the prestigious New York City Health Business Leaders Boldest Digital Health Influencer Award.

As a medical futurist, Dr. Fombu champions the potential for the internet of things, AI and machine learning to revolutionize the healthcare industry. He’s passionate about m-health, personalized medicine, genomics, nanotechnology, big data, artificial intelligence, machine learning, the internet of things and digital medicine. He serves as an external advisory board member on the Massachusetts Institute of Technology’s MIT.nano project.

Dr. Fombu trained at Emory-Crawford Long Hospital and holds an MBA from Cornell University’s Johnson School of Business and a certification on artificial intelligence from MIT’s Computer Science and Artificial Intelligence Lab. He’s taught allied health students, founded a health and education focused non-profit organization and advocates for patients with rare and chronic diseases. Dr Fombu works extensively with venture capitalists and start-ups in digital health and biotech.

In addition to The Future of Healthcare: Humans and Machines Partnering for Better Outcomes, Dr. Fombu has published multiple scientific papers in world renowned, peer reviewed scientific journals. He lives in New York City.

Esther Dyson (@edyson on twitter) is executive founder of Wellville (@WaytoWellville), a ten-year, five-community project dedicated to showing the value of investing in health (as opposed spending on care). Wellville advises the five US-based Wellville communities on accelerating their own health initiatives, in Clatsop County, OR; Lake County, CA; Muskegon County, MI; North Hartford, CT; and Spartanburg, SC. Dyson is the W2W lead for Muskegon, and is actively involved in policy and fundraising for the project. Wellville’s overall mission is to encourage society to think longer-term and more broadly – from self to community – by illustrating the social and financial benefits of collective investment in human capital.

Wellville favors implementation over innovation: applying approaches known to work, at scale in small communities where scale is relatively easy to achieve in terms of both resources and political buy-in. Each community sets its own priorities and goals around issues such as early childhood experiences, obesity/diabetes, mental health, dental health, smoking, addiction and overall human capacity and health disparities; W2W assists in finding partners and funders, and in managing accountability. Over its 10-year life (through 2024), Wellville will measure its progress both year by year and at the end, using both specific program-based metrics and overall goals . Its mission is not just to help five small (<200,000 people) communities get healthy, but to scale by inspiring other communities and funders to copy its example and to think long-term, for the benefit of all. Its motto is “Don’t rent your health. Invest in it!” Aside from that full-time role, Dyson spends her extra time investing in and nurturing start-ups, with a recent focus on health care (somewhat constrained to avoid conflicts with Wellville). On the health side, she is an investor in 23andMe, 4D Healthware, Basil Health, Big Health, Boundless.ai, Care.Coach, CareMESH, Clover Health, Devoted Health, Doppel, Eligible, Enso Relief, Epistemic.ai, Ezra.com, Hawthorne Effect, HealthCelerate, HealthTap, i2Dx, MealShare, Medesk, MedicaSafe, mEquilibrium, Nanowear, NeuroGeneCES, Nuna, Omada Health, PatientsKnowBest, Prognos.ai, Proofpilot, Resilient, Sapiens DS, Solera (also an advisor), StartupHealth, Supportiv, Syllable.ai, Tega Pharmaceutical, Tocagen, Trusty.care, Turbine.ai, Valkee, Virgo, X-VAX and Zipongo.

France A. Córdova is an astrophysicist and the 14th director of the National Science Foundation (NSF), the only government agency charged with advancing all fields of scientific discovery, technological innovation, and science, technology, engineering and mathematics (STEM) education. NSF is a $7.5 billion independent federal agency; its programs and initiatives keep the United States at the forefront of science and engineering, empower future generations of scientists and engineers, and foster U.S. prosperity and global leadership.

Córdova is president emerita of Purdue University, and chancellor emerita of the University of California, Riverside, where she was a distinguished professor of physics and astronomy. Córdova was the vice chancellor for research and professor of physics at the University of California, Santa Barbara.

Previously, Córdova served as NASA’s chief scientist. Prior to joining NASA, she was on the faculty of the Pennsylvania State University where she headed the department of astronomy and astrophysics. Córdova was also deputy group leader in the Earth and space sciences division at Los Alamos National Laboratory. She received her Bachelor of Arts degree from Stanford University and her doctorate in physics from the California Institute of Technology.

More recently, Córdova served as chair of the Board of Regents of the Smithsonian Institution and on the board of trustees of Mayo Clinic. She also served as a member of the National Science Board (NSB), where she chaired the Committee on Strategy and Budget. As NSF director, she is an ex officio member of the NSB.

Córdova’s scientific contributions have been in the areas of observational and experimental astrophysics, multi-spectral research on x-ray and gamma ray sources and space-borne instrumentation. She has published more than 150 scientific papers. She has been awarded several honorary doctorates, including ones from Purdue and Duke Universities. She is a recipient of NASA’s highest honor, the Distinguished Service Medal, and was recognized as a Kilby Laureate. The Kilby International Awards recognize extraordinary individuals who have made “significant contributions to society through science, technology, innovation, invention and education.” Córdova was elected to the American Academy of Arts and Sciences and is a National Associate of the National Academies. She is also a fellow of the American Association for the Advancement of Science (AAAS) and the Association for Women in Science (AWIS).

Córdova is married to Christian J. Foster, a science educator, and they have two adult children.

Geoff Martha is Executive Vice President and President of Medtronic’s Restorative Therapies Group (RTG) – one of four Medtronic business groups – with over $8B in annual revenue and approximately 14,000 employees worldwide. He also serves as a member of the company’s Executive Committee.

Geoff has global responsibility for RTG’s four divisions, which include Brain Therapies, Pain Therapies, Specialty Therapies and Spine. He provides overall strategic direction and operational management, as well as leads the integration of the group’s activities within the overall strategy of Medtronic. Previously, Geoff was Senior Vice President of Strategy and Business Development for Medtronic and had responsibility for leading the development of Medtronic’s global strategic plan, business development and acquisition-integration.

As head of Strategy and Business Development, Geoff led the acquisition of Covidien, a $10 billion global manufacturer of surgical products and supplies. The acquisition of Covidien was the largest medical technology acquisition in the history of the industry. In July 2014, he was named Chief Integration Officer to lead the integration of Covidien into Medtronic.
Geoff serves as the Executive Sponsor of the African-Descent Network – an internal national resource group that focuses on recruitment, engagement, retention and development for Medtronic employees of African descent. An ardent supporter of Medtronic-sponsored philanthropic initiatives, Geoff also is a member of the Medtronic Foundation Board of Directors and serves as Medtronic’s Executive Sponsor to FIRST Robotics.

Prior to joining Medtronic, Geoff served as Managing Director of Business Development at GE Healthcare, where he was responsible for global business development, including acquisitions, divestitures, joint ventures and equity investments. In his 19-year career with GE, which included significant time with GE Capital, Geoff held several executive roles in business leadership, corporate development, strategic marketing, and sales management.

Passionate about socio-economic issues, Geoff serves on the boards of two Minneapolis-based nonprofit organizations: Children’s HeartLink and Northside Achievement Zone (NAZ). Children’s HeartLink provides access to care for children around the world with congenital heart defects. NAZ is a community collaborative that works to end generational poverty and build a culture of achievement in North Minneapolis so low-income children of color graduate college and are career-ready.

Geoff received a bachelor’s degree in Finance as a member of the Scholar’s Program from Pennsylvania State University. He graduated in 1992 with highest honors. Geoff was captain of the Penn State men’s hockey team and was later inducted into its Hockey Hall of Fame in 1998. The University awarded him the 2016 Penn State Hockey Distinguished Alumni Award.

Jonathan Bush is the former Chief Executive Officer of athenahealth, Inc. He co-founded the company in 1997 and took it public in 2007 in the most successful initial public offering that year. Today, athenahealth remains one of the healthcare information technology industry’s fastest growing companies.

Bush’s views on healthcare and the idea for athenahealth were born from failures with the earliest iteration of its business model. Bush co-founded and operated a birthing clinic with the idea of franchising a network of clinics that viewed pregnancy holistically. Bush would soon realize that his birthing clinic vision was challenged by his business’s own inability to track outstanding claims to insurers and get paid in a reasonable time-frame. This challenge would shape the formation of athenahealth as it is known today. As a result of the challenges with the clinics, Bush and his partners set about designing a solution to address the costly administrative inefficiencies that plagued their business. In doing so, they came to realize their circumstance was more typical than unique and that the solution they designed had great application and utility for the broader health delivery system. Given his vision for an information infrastructure that makes healthcare work as it should, Bush is focused on creating a true, win-win marketplace that enables a broad and efficient exchange of health information.

In addition, Bush has announced a forthcoming book: “Where Does It Hurt? An Entrepreneur’s Guide to Fixing Health Care.” The book, written together with Steve Baker, author of The Numerati, will be published May 15th.

“Where Does It Hurt” is a provocative, irreverent, sometimes harrowing and, of course, always humorous journey through the dark underbelly of the American healthcare system – why it’s broken, what the fix will involve, and where innovation is already taking hold.

John is Managing Director and a Senior Partner leading Landmark Ventures’ Technology Investment Banking practice. He focuses on providing M&A, private placement and strategic advisory services to growth stage private and public companies across the technology, hardware/semiconductor, digital media, software and Cleantech markets. John leverages extensive relationships across the corporate, PE and VC communities, with a significant cross border focus spanning US, Canada, Europe, Asia and Israel. In his 17 year career, John has successfully closed more than 50 transactions with transaction value exceeding 6 Billion.

Prior to joining Landmark, John was a Senior VP with Jefferies & Co, Inc., a leading global, full-service investment bank targeting middle-market and growth oriented companies. At Jefferies, he focused on M&A and Capital Markets transactions within the technology sectors, including lead coverage responsibility in the hardware, semiconductor/components and communications segments. John joined Jefferies as a VP from Broadview International, a leading technology M&A advisor, which was acquired by Jefferies in December 2003. Prior to Broadview, John was a Senior Associate with Robertson Stephens, focused on technology M&A, private placements and public equity transactions. John started his career with PwC Securities, providing M&A and private placement services to companies across the technology, industrial and consumer markets.

John graduated from Brown University, with a BA in Business Economics.

Justin C. Sanchez is a Battelle Technical Fellow. As a noted expert in biotechnology, he creates strategic vision to guide Battelle’s life sciences research business. Serving on the leadership team, Dr. Sanchez leads the organization’s technical investment strategies and initiates and drives collaboration across Battelle, as well as with government, industry, and academia partners.

Prior to joining Battelle, Dr. Sanchez was the Director of the Biological Technologies Office (BTO) at DARPA. He advanced the mission of BTO through strategy development focused on vital breakthrough technologies and capabilities for national security, particularly in the areas of neurotechnology, gene editing/synthetic biology, and infectious disease. Major accomplishments include developing foundational human neurotechnology for the United States BRAIN Initiative, delivering the world’s most advanced prosthetic arm to military Veterans, accelerating gene editing techniques for national security/human health, and forming partnerships to deliver countermeasures in the African Ebola crisis. He was responsible for starting 31 new DARPA programs and investing more than $1.65 billion at national labs, industry, and academic institutions.

Prior to joining DARPA, he was an associate professor of Biomedical Engineering and Neuroscience at the University of Miami. He directed the Neuroprosthetics Research Group where he oversaw development of neural-interface medical treatments. He has published more than 100 peer-reviewed papers, holds seven patents and authored two books on the design of neurotechnology.

Dr. Sanchez holds a Doctor of Philosophy and Master of Engineering degrees in Biomedical Engineering, and a Bachelor of Science degree in Engineering Science, all from the University of Florida.

Kathleen Gondek, PhD, is currently the Global Head of Outcomes Research and Epidemiology at Takeda.

Kathleen spent the last four years at Shire as Global Head of Outcomes Research and Epidemiology. Prior to joining Shire she was Vice President, US Medical Science Liaisons and Medical Affairs Operations at Bayer HealthCare pharmaceuticals. Prior to this role Kathleen held a number of positions, of increasing responsibility, within the Health Economics and Outcomes Research (HEOR) function at Bayer that span a 15-year career with the organization. These include Director HEOR US, Head of Global HEOR for Life Cycle Management, Anti-infectives, Men’s Health and Oncology and Vice President, Global Health Economics and Outcomes Research, Specialty Medicine. Prior to joining Bayer, Kathleen worked at Boehringer Ingelheim Pharmaceuticals. Kathleen is a coauthor on 45 peer reviewed publications and over 100 presentations.

Kathleen holds a Bachelor’s Degree in Pharmacy from the State University of New York at Buffalo and a PhD in Pharmacy Practice and Administrative Science from the University of Maryland at Baltimore. While at Bayer, Kathleen was a lecturer at Yale University in the School of Public Health.

With over three decades of experience working in the nonprofit sector, Peter Wilderotter has leveraged his expertise to expand and advance the mission of several organizations.

Peter was appointed as the President and Chief Executive Officer of the Christopher & Dana Reeve Foundation in 2007 after revamping how the organization approached fundraising. Reporting to the Board of Directors, Peter is responsible for setting the overarching vision for the Reeve Foundation and rallying support for initiatives that speed the delivery of treatments for spinal cord injury.

Before locking arms with the Reeve Foundation, Peter was the Vice President of Development at WNYC Radio, America’s largest public radio station. Previously, Peter held leadership roles at Planned Parenthood Federation of America and the NAACP, and started his career at the American Cancer Society.

Lance Becker, MD, joined Northwell Health in 2015 as chair of the Department of Emergency Medicine at North Shore University Hospital and Long Island Jewish Medical Center, professor and chair of emergency medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, and an investigator at the Feinstein Institute for Medical Research.

A national and international leader in academic emergency medicine, critical care and resuscitation science, Dr. Becker has research interests that are translational and extend across the basic science laboratory into animal models of resuscitation and to human therapies. He has been a leader in the field of resuscitation for more than 25 years, pioneering advances in improving the quality of CPR, AED use, defining the “three-phase” model for cardiac arrest care and therapeutic hypothermia. He has worked closely with the American Heart Association in emphasizing the importance of a “systems of care” approach to improving survival within communities.

Dr. Becker’s cellular studies have helped define reperfusion injury mechanisms, mitochondrial oxidant generation, reactive oxygen and nitrogen species responses to ischemia, apoptotic activation following ischemia, signaling pathways, new cellular cytoprotective strategies and hypothermia protection. He has received numerous honors and awards from organizations such as the American Heart Association, the American College of Emergency Physicians and American Society of Critical Care.

A recipient of prestigious teaching awards, Dr. Becker has mentored many successful researchers. He is a renowned, well-funded researcher who holds many patents for his discoveries. His professional affiliations include membership in the American Heart Association, Society of Academic Emergency Medicine, the US Institute of Medicine, the National Academy of Science, the American College of Emergency Physicians and the American Physiological Society. In addition, he holds many offices in professional and scientific societies, and has organized many national and international scientific meetings. He is an elected member of the Institute of Medicine/National Academy of Medicine.

Before joining Northwell, Dr. Becker was founder and director of the Center for Resuscitation Science at the Hospital of the University of Pennsylvania in Philadelphia, and professor of the Center for Mitochondrial and Epigenomic Medicine at the Children’s Hospital of Philadelphia. He was previously founder and director of the Emergency Resuscitation Center at the University of Chicago and Argonne National Laboratory.

Dr. Becker received his medical degree from the University of Illinois, College of Medicine.

Ramon Soto is a skilled marketing executive with deep healthcare and financial services experience. He has a demonstrated ability to create vision, establish long-term strategies and lead cross-functional teams. Ramon has a proven track record of profitable growth in consumer and business-to-business markets. He is a passionate thought leader with strong analytic and growth skills.

Ramon is the senior vice president, chief marketing and communications officer for Northwell Health, where he is responsible for the development and execution of Northwell’s brand strategy, as well as for all aspects of marketing and communications including public relations, digital engagement, strategic marketing, clinical marketing and customer acquisition.
Ramon is a member of Northwell Health’s executive council, responsible for shaping the growth strategy and execution for the enterprise. Northwell Health is New York’s largest healthcare provider with a network of 23 hospitals, 750 community, research and clinical facilities. Northwell is NY State’s largest private employer with over 69,000 employees. With 5 million patient visits in 2018, Northwell Health is also one of the fastest growing healthcare providers in the country. Its market reach has expanded through acquisition of new hospital facilities and organic growth of ambulatory facilities, physician practices and joint ventures.

Ramon was formerly the chief marketing officer for Magellan Health, a healthcare services company focused on the unmet needs of individuals in the fast growing, highly complex and high cost areas of healthcare.

Prior to Magellan, Ramon was a senior vice president with Aetna, managing the global marketing function for the Aetna’s commercial businesses. Ramon ran the marketing function for Aetna’s national accounts, middle market, small group, specialty product and international business divisions, representing $32 billion in annual revenue.

Before his time at Aetna, Ramon spent several years at GE Capital leading the marketing function for several of GE’s consumer and commercial facing businesses.

Ramon is a graduate of the Yale School of Management’s MBA program for executives with a concentration in Healthcare. He serves on the Yale School of Management Alumni Board of Directors. He is also a graduate of GE Capital’s Leadership Interchange, a high potential manager training program. He is Six Sigma certified, was awarded a U.S. government patent for co-development of GE Capital’s product development process and was an instructor at GE’s Small Business College.

Ramon received his B.A. from the State University of New York at Binghamton in 1988.

Lidia Fonseca is Executive Vice President, Chief Digital and Technology Officer, responsible for developing and implementing an enterprise-wide digital strategy and roadmap. Lidia leads all digital, data and technology solutions across the company.

In her prior role, she was the Senior Vice President and CIO at Quest Diagnostics (NYSE:DGX), where she led technology, informatics and digital solutions. Lidia led the effort to create Quest’s innovative Quanum™ brand of healthcare IT and data analytics technologies, as well as leading-edge consumer technologies and digital solutions, including the MyQuest app with 6.5 million subscribers. This suite of solutions was designed to address gaps in care, improve quality, optimize utilization, and support the industry’s evolution to value-based healthcare. Additionally, she was responsible for Quest’s bioinformatics, focused on the use of data for advanced diagnostic services, as well as efforts to digitally enable and standardize operations to better serve its customers.

Lidia received the 2017 Forbes CIO Innovation Award, and she is a founding member of Synaptic Health Alliance, leading healthcare companies using Blockchain technology to improve provider data quality.

Lidia is a member of the Board of Directors of Tegna, Inc. (NYSE: TGNA). She earned a BA from University of California, Berkeley and an MBA and Master Business Informatics from Rotterdam School of Management, Erasmus Graduate School of Business.

Richard Barakat is an internationally recognized surgeon and clinical investigator who was Chief of the Gynecology Service at Memorial Sloan Kettering from 2001 to 2013 and held the Ronald O. Perelman Chair in Gynecologic Surgery. Dr. Barakat was the lead investigator on several influential research projects at MSK, including a study to compare the benefits of laparoscopic versus standard surgery for patients with endometrial cancer, a study evaluating symptomatic lower-extremity lymphedema in women treated for uterine corpus cancer, and a study testing the efficacy of the Gynecologic Cancer Lymphedema Questionnaire in detecting lower-extremity lymphedema symptoms. Dr. Barakat is author or co-author of more than 340 peer-reviewed articles and numerous textbook chapters and is also an editor of a surgical atlas on gynecologic cancer and of the latest edition of Principles and Practice of Gynecologic Oncology, one of the leading texts in the field.

In addition he served as a member and examiner for the American Board of Obstetrics and Gynecology and for five years served as Vice Chairman of the Cancer Prevention Committee of the Gynecologic Oncology Group. He was President of the Society of Gynecologic Oncology from 2013 to 2014 and past President of the International Gynecologic Cancer Society (2014-2016). From 2013 -2017, he served as Director of the MSK regional network.

In 2018 Dr. Barakat joined Northwell Health to lead all cancer services and research and serve as professor of Obstetrics and Gynecology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.

One of TV’s most respected medical journalists, Dr. Max Gomez has produced award-winning health and science segments for network stations in New York and Philadelphia. Dr. Max has reported for Dateline, The Today Show and 48 Hours. He is currently the senior medical correspondent for WCBS, the flagship CBS network station in New York.

Over more than three decades, he’s earned nine Emmy Awards, three NY State Broadcaster’s Association awards and UPI’s “Best Documentary” award.

In addition to NYC’s ‘Excellence in Time of Crisis’ for his September 11 coverage, Dr. Max has been singled out nationally for special award recognition by the Leukemia and Lymphoma Society and The National Marfan Foundation. He was also named the American Health Foundation’s “Man of the Year”.

Dr. Gomez has served on the national board of directors for the American Heart Association, the Princeton Alumni Weekly, and Partnership for After School Education. He has chaired the national communications committees for the American Heart Association and the American Association for the Advancement of Science.

Dr. Max helped organize and moderate four international scientific conferences on stem cells and cell-based medicine co-sponsored by and held at the Vatican.

A noted moderator, speaker and media trainer, Dr. Max also mentors undergraduate journalism students as well as medical students and physicians who are interested in medical journalism.

Dr. Max is the co-author of “Cells are the New Cure – The Cutting Edge Medical Breakthroughs that are Transforming Our Health” as well as “Our Stem Cells – The Mysteries of Life and Secrets of Healing”, and “The Prostate Health Program: A Guide to Preventing and Controlling Prostate Cancer.”

Dr. Max is an honors graduate of Princeton University, received his PhD in Neuroscience from the Wake Forest University School of Medicine and was an NIH postdoctoral fellow at Rockefeller University.

Sendhil Mullainathan is the Roman Family University Professor of Computation and Behavioral Science at Chicago Booth. His current research uses machine learning to understand complex problems in human behavior, social policy, and especially medicine, where computational techniques have the potential to uncover biomedical insights from large-scale health data. He currently teaches a course on Artificial Intelligence.

In past work he has combined insights from economics and behavioral science with causal inference tools—lab, field, and natural experiments—to study social problems such as discrimination and poverty. Papers include: the impact of poverty on mental bandwidth; how algorithms can improve on judicial decision-making; whether CEO pay is excessive; using fictitious resumes to measure discrimination; showing that higher cigarette taxes makes smokers happier; and modeling how competition affects media bias.

Mullainathan enjoys writing. He recently co-authored Scarcity: Why Having too Little Means so Much and writes regularly for the New York Times. Additionally, his research has appeared in a variety of publications including the Quarterly Journal of Economics, Science, American Economic Review, Psychological Science, the British Medical Journal, and Management Science.
Mullainathan helped co-found a non-profit to apply behavioral science (ideas42), co-founded a center to promote the use of randomized control trials in development (the Abdul Latif Jameel Poverty Action Lab), serves on the board of the MacArthur Foundation, has worked in government in various roles, is affiliated with the NBER and BREAD, and is a member of the American Academy of Arts and Sciences.

Prior to joining Booth, Mullainathan was the Robert C. Waggoner Professor of Economics in the Faculty of Arts and Sciences at Harvard University, where he taught courses about machine learning and big data. He began his academic career at the Massachusetts Institute of Technology.

Mullainathan is a recipient of the MacArthur “Genius Grant,” has been designated a “Young Global Leader” by the World Economic Forum, was labeled a “Top 100 Thinker” by Foreign Policy Magazine, and was named to the “Smart List: 50 people who will change the world” by Wired Magazine (UK). His hobbies include basketball, board games, googling, and fixing up classic espresso machines.

Paurvi Bhatt is the Vice President of Medtronic Philanthropy and President of Medtronic Foundation, leading the philanthropic and community affairs strategies of Medtronic, PLC.

Medtronic is the global leader in medical technology, focused on innovative solutions to fulfill its global Mission: to alleviate pain, restore health and extend life. The company’s philanthropic efforts are centered on leveraging its people, products and programs to expand access to chronic disease care to underserved communities worldwide.

Paurvi is a seasoned global health and development leader, with a distinguished career delivering innovative and successful cross-disciplinary solutions to challenging issues of scale and sustainability. Her focus includes strategic philanthropy and investment; corporate social responsibility; health benefit reimbursement, and partnership design particularly in emerging markets and resource poor settings. She has shaped best practice health and social responsibility portfolios in several companies including Levi Strauss and Co. and Abbott, as well as, with the government and nonprofit sector, at USAID, US GAO, and CARE. Her technical training is in health systems and economics – with specific focus on HIV/AIDS, women’s health and impact measurement.

She is known for her commitment to building the next generation of women leaders in global health, and for advocating for “working daughters”. She serves on several advisory groups and Boards focusing on leadership and global health including Last Mile Health, GlobeMed, IMPACT2030, The Conference Board – CSR Advisory Group, Women Leaders in Global Health, Global Health Council (GHC) Board, and the University of Minnesota School of Public Health Campaign Cabinet. Paurvi holds a Master of Public Health in health systems and economics from Yale University and Bachelor Degree in neuroscience from Northwestern University, is PhD (ABD) from Johns Hopkins University.

Susan L. Solomon is the Chief Executive Officer and Founder of the New York Stem Cell Foundation Research Institute (NYSCF). Ms. Solomon is a veteran healthcare advocate and stem cell research pioneer who serves on the boards of a number of prominent diabetes and regenerative medicine organizations, including the College Diabetes Network, the Global Alliance for IPSC Therapies, and the strategic planning committee for the inaugural NYSTEM program. She also serves on the Board of Directors of the Regional Plan Association, where she is a member of the nominating and governance committee.

A lawyer by training and a chief executive and entrepreneur by experience, Ms. Solomon has decades of leadership experience in starting and building effective and focused organizations. Ms. Solomon started her career as an attorney at Debevoise and Plimpton, then held executive positions at MacAndrews and Forbes and APAX (formerly MMG Patricof and Co.). She was the founder and President of Sony Worldwide Networks, the Chairman and Chief Executive Officer of Lancit Media Productions, an Emmy award-winning television production company, and then served as the founding Chief Executive Officer of Sothebys.com, prior to starting her own strategic management consulting firm Solomon Partners LLC in 2000. She received her BA cum laude from New York University and her JD from Rutgers University School of Law, where she was as an editor of the Law Review.

Ms. Solomon has received numerous awards for her work with NYSCF, including the New York State Women of Excellence Award from the Governor of New York, the Triumph Award from the Brooke Ellison Foundation, and recognition as a Living Landmark from the New York Landmarks Conservancy.

Dr. Thomas Lee is an internist and cardiologist who practices at Brigham and Women’s Hospital in Boston, Massachusetts. He is a Professor of Medicine, part time, at Harvard Medical School and Professor of Health Policy and Management at the Harvard School of Public Health. He currently serves as Chief Medical Officer to Press Ganey, Inc. Prior to joining Press Ganey in 2013, Dr. Lee was the Network President for Partners Healthcare System, the integrated delivery system founded by Brigham and Women’s and Massachusetts General Hospitals in 1994.
Dr. Lee has performed clinical epidemiological research leading to more than 300 articles in peer-reviewed journals, and three books. He is a member of the Editorial Board of The New England Journal of Medicine, the Board of Directors of Geisinger Health System, the Board of Directors of Health Leads; the Board of Overseers of Weill Cornell Medical College; the Special Medical Advisory Group (SMAG) of the Veterans Administration; and the Panel of Health Advisors of the Congressional Budget Office.

He received is BA from Harvard College (1975) and his MD from Cornell University Medical College (1979), and then trained in internal medicine and then cardiology at Brigham and Women’s Hospital. He received a MSc in Epidemiology from Harvard School of Public Health in 1987.

As the past Director of the Human Genome Project for US. Department of Energy, Dr. Hawkins has built a recognized career in the healthcare industry over the past 25 years spanning business, academic innovation and as an entrepreneur.

Dr. Hawkins is currently the Founder & Managing Partner at IGenes LLC, a consulting and investment firm working with a portfolio of global companies. Clients include General Electric, Northwell Health, Ping An, Google, Grifols, Ativa Medical, Data Cubed and BioElectron Pharmaceuticals. Dr. Hawkins is also a visiting professor at NYU.

IGenes LLC provides consulting services to companies ranging from technology roadmaps, strategy development and evaluation, market modeling, product development roadmaps and regulatory approval. On the investment services front, IGenes has completed financing in excess of $250M drawing on a wide network of early-mid stage investors.

Previously, Dr. Hawkins has held several senior executive roles at Siemens Healthcare, Philips and General Electric. He was also a successful entrepreneur building and selling a diagnostic company based in Shanghai & San Francisco.

Dr. Hawkins has published over 50 peer-reviewed articles on automation, genomics, human diseases and the human genome project in addition to writing a book, “Solving the Healthcare Equation” which is expected to be completed in 2020.

Vik is a Managing Director at Foresite, evaluating and pursuing investments at the intersection of technology and life sciences, including in personalized and precision healthcare.
Prior to joining Foresite Capital, Vik was the Chief Scientific Officer of GRAIL, a life sciences company working to detect cancer early when it can be cured, and remains on its Scientific Advisory Board. He is also the Co-Founder and former Chief Scientific Officer of Verily (formerly Google Life Sciences) and served as Chair of its Scientific Advisory Board. A former academic principal investigator, Vik retains appointments as Associate Professor (consulting) at the Stanford School of Medicine, and as an Affiliate Scientist of the Lawrence Berkeley National Laboratory and the University of California, Berkeley, for which he serves on the advisory board of the College of Chemistry. He is an advisor to the Department of Defense through the Defense Science Board’s Task Force on Biology.

Vik’s research interests lie at the interface of the physical sciences, engineering, and the life sciences. He and his collaborators have developed nanotechnology probes for the early detection and molecular imaging of disease, spectroscopic tools for imaging objects on the nanoscale, microfabricated and miniaturized analytical and imaging systems for point-of-care testing, methods and devices that dramatically enhance the sensitivity and specificity of MRI, and new tools for clinical bioinformatics and integrative systems biology. Aspects of this work have been commercialized through several startups. At GRAIL, Vik led laboratory and data science teams at the forefront of industrial cancer genomics and diagnostics development.

He holds a Ph.D. in physical chemistry from the Massachusetts Institute of Technology. Vik’s scientific and engineering awards include the Anatole Abragam Prize (2012), the R&D 100 Award for the most promising commercialized technologies (2011 and 2013), and the Department of Energy’s LBL Innovation Grant (2013). In 2011, he was named as a Visiting Professor of the Chinese Academy of Sciences.

Wolfgang Baiker, M.D., Ph.D., M.B.A., is the President and Chief Executive Officer (CEO) of BI USA and the US Country Managing Director. Dr. Baiker leads the team that ensures the company’s success in the US for all of BI’s businesses, including Human Pharma, Animal Health and Bio Manufacturing.

Prior to this position, Dr. Baiker served as Senior Vice President, Human Pharma Supply & Global Quality, as well as Head of the Biopharma Business Unit. He joined Boehringer Ingelheim in 1989 as Section Head for Clinical Development in Biberach, Germany.

Since then, Dr. Baiker has held a number of senior leadership roles across several critical business functions, including Head of International Project Management; Head of Global Development; Member of the Board of Managing Directors (BMD) responsible for Corporate Board Division Biopharmaceuticals and Operations; and currently, as a key member of the Human Pharma Executive Committee.

Dr. Baiker completed his medical studies and doctorate at the Universities of Bochum, Berlin, Ulm, Munich and Sheffield and received his MBA from Pace University in New York.

Paul Black serves as Allscripts Chief Executive Officer. Paul was appointed CEO in December 2012 after having served on Allscripts Board of Directors for eight months. As Chief Executive Officer, Paul leads the direction of the company and its global commitment to delivering an Open, Connected Community of Health^TM.

Prior to joining Allscripts, Paul spent more than 13 years with Cerner Corporation in various executive positions, retiring as Cerner’s Chief Operating Officer in 2007. During his tenure with Cerner, he helped build the company into a market leader in healthcare information technology with more than $1.5 billion in annual revenue. Prior to Cerner, Paul spent 12 years with IBM Corporation in a variety of leadership positions in sales, product marketing and professional services.

Paul has held positions on multiple private company and non-profit boards of directors. The businesses ranged from healthcare information technology and healthcare services to software and SaaS-based consumer Internet marketing. Paul’s leadership experience on those boards includes serving as director, chairman and executive Chairman. Paul has also provided investment advice to several private equity firms on both coasts.

He is currently Immediate Past Chairman of Truman Medical Centers, as well as an Officer of the Corporation. Truman Medical Centers is a 400-bed safety net academic hospital in Kansas City. Paul earned a Bachelor of Science degree from Iowa State University and a Master of Business Administration from the University of Iowa. He is married with two children and enjoys running, travel and coaching youth sports.

Sue Siegel is GE’s Chief Innovation Officer and CEO of Business Innovations, as of October 2017. In this role, she is responsible for leading the development and acceleration of innovation across the company. An innovator at heart, she is a seasoned executive focused on uncovering new and unconventional paths to growth. She has 30+ years of corporate, entrepreneurial and venture capital experience all geared at one thing: turning untapped potential into real value.

Sue joined GE in 2012 as CEO of healthymagination. Sue helped launch GE Ventures, an innovation engine focused on accelerating promising start-ups, creating new business models, developing new markets, and nurturing ideas into scalable initiatives both inside and outside of GE.  In this role, Sue and her team led the creation and launch of seven new companies including Avitas Systems, Vineti and Evidation Health, funded and accelerated growth for 100+ companies and led the creation of a novel licensing model for GE’s library of patents – connecting technology and ideas to create new avenues to growth.

Prior to joining GE, Sue worked for a Silicon Valley-based venture capitalist at MDV, Sue led investments and served as Board member for companies in personalized medicine, digital health, and life sciences. Prior to that, Sue served as President and Board Member of Affymetrix (NASDAQ: AFFX), where she led the company’s transformation from a pre-revenue startup to a global, multi-billion dollar market cap genomics leader. She also led strategy, technology development, licensing, manufacturing, and new market creation and development at leading organizations including Bio-Rad, DuPont and Amersham.

Sue holds an M.S. from Boston University School of Medicine and a B.S. from the University of Puerto Rico. She has been recognized in Fortune as one of “34 Leaders Who Are Changing Health Care” and as one of “The 100 Most Influential Women in Silicon Valley” by Silicon Valley Business Journal. She is an Aspen Institute Crown Fellow and was featured as a “Multiplier” in the bestselling book: “Multipliers: How the Best Leaders Make Everyone Smarter.” She lives in Silicon Valley with her husband and has two sons. She is an avid hiker and loves to spend time on the scenic trails of Northern California.

Current board positions and memberships:

Align Technology (NASDAQ: ALGN), MIT The Engine, Harvard Partners’ Healthcare Innovation Advisory Board, Scientific Advisory Board, Brigham and Women’s Hospital, Stanford Medicine Board of Fellows, University of California’s Innovation Council, USC’s Schaeffer Center for Health Policy and Marshall School of Business Board of Leaders, Women Corporate Directors, and Member of YPO Gold.

Stephanie Cuskley is the Chief Executive Officer of the Helmsley Charitable Trust which aspires to improve lives by supporting exceptional nonprofits and other mission-aligned organizations in the U.S. and around the world in health, place-based initiatives, and education and human services. Appointed in late 2015, she brings to her role more than 30 years of diverse management and leadership experience from both the corporate and nonprofit sectors.

Stephanie began her career as an investment banker, most recently with JPMorgan Chase, where she spent many years in leveraged finance. In 2001, shortly after the merger of JPMorgan and Chase, Stephanie led the firm’s new leadership and culture program, initially focused on the firm’s top 200 executives and subsequently expanded to all employees. More recently, from 2009 to 2015, Stephanie was CEO of NPower, a nonprofit focused on mobilizing the technology community and providing individuals, nonprofits, and schools opportunities to build tech skills and achieve their potential.

Today, Stephanie serves on the board of Aegion, Inc. She earned her B.A. from the University of Toronto and holds an MBA from Cornell University.

Josh has worked with NEA since 1995 and recently became a General Partner on their healthcare team leading the medtech/healthtech practice. Josh is the Founder & Executive Chairman of ExploraMed, a medical device incubator creating 8 companies. Transactions from the ExploraMed portfolio include NeoTractm acquired by Teleflex, Acclarent, acquired by J&J, EndoMatrix, acquired by C.R. Bard & TransVascular, acquired by Medtronic. Other ExploraMed/NEA ventures include Moximed, Nuelle and Willow. Josh serves on the faculty of the Stanford University Medical School as a Adjunct Professor of Medicine and is Co-Founder of Stanford’s Biodesign Innovation Program. Josh serves on the board of Setpoint Medical, DOTS Devices, Eargo, ExploraMed, Intrinsic Therapeutics, Moximed, Willow and Coravin. Josh holds over 300 patents and patent applications. He received an MBA from Columbia University, an MD from the NYU School of Medicine, and a bachelor’s degree in Mechanical Engineering from MIT.

Dr. Patrick Carroll is the Chief Medical Officer for Walgreen’s Healthcare Clinics.  In this role, Dr. Carroll oversees all matters pertaining to provision of care, clinical outcomes, patient safety, healthcare information systems and strategic initiatives and programs that will enhance the care model.  In addition, Dr. Carroll is instrumental in implementing care management programs, managing relationships with health systems and collaborating with the Clinical Office in the development of enterprise clinical programs.

Prior to joining Walgreen’s in May 2015, Dr. Carroll served as the Chief Medical Officer of Integrated Care Partners, Hartford HealthCare’s clinical integration organization.  He was also the Medical Director for Hartford HealthCare’s Medicare Shared Savings Program which currently has over 20,000 patients in a Medicare/CMS shared-risk pilot program.  He played a key role in leading the Hartford HealthCare’s efforts in the transition to value-based care in a time of a rapidly changing healthcare landscape.

From 2010–2012, Dr. Carroll served as the Chief Medical Officer for the Granite Medical Group in Quincy, Massachusetts.  Granite Medical Group is a 40-provider Multispecialty/Primary Care Group which is part of Atrius Health, a 1000 Medical Provider Group.

Dr. Carroll received his bachelor’s degree from the College of the Holy Cross and his medical degree from Dartmouth Medical School.  He completed his residency training at Middlesex Hospital in family practice, where he served as Chief Resident.

Dr. Carroll is Board Certified in Family Practice and in Adolescent Medicine.

Aletha Maybank, MD, MPH currently serves as a Deputy Commissioner in the New York City Department of Health and is the Founding Director of the Center for Health Equity. The Center’s mission is to bring an explicit focus to health equity in all of the Department’s work by tackling structural barriers, such as racism, ensuring meaningful community engagement, and fostering interagency coordination in neighborhoods with the highest disease burden.

Prior to this role, she was an Assistant Commissioner in the NYC Health Department and served as the Director of the Brooklyn Office, a place-based approach. Dr. Maybank also successfully launched the Office of Minority Health as its Founding Director in the Suffolk County Department of Health Services in NY from 2006-2009.

Dr. Maybank serves as Vice President of the Empire State Medical Association, the NYS affiliate of the National Medical Association. In the media and on the lecture circuit, she has appeared or been profiled on Disney Jr.’s highly successful Doc McStuffins Animated Series, ESSENCE Facebook live and their Festival’s Empowerment Stage, MSNBC’s Melissa Harris-Perry show, and various other outlets. She has also advised on the award-winning documentary Soul Food Junkies by Byron Hurt and Black Women in Medicine by Crystal Emery. For her accomplishments, she has won numerous awards.

Dr. Maybank holds a BA from Johns Hopkins University, a MD from Temple University School of Medicine, and a MPH from Columbia University Mailman School of Public Health. A pediatrician board certified in Preventive Medicine/Public Health, she completed her preventive medicine residency at the SUNY Stony Brook University School of Medicine and her pediatrics residency at the Albert Einstein School of Medicine’s Schneider Children’s Hospital.

Troyen A. Brennan, M.D., M.P.H., is Executive Vice President and Chief Medical Officer of CVS Health.  Prior to joining CVS Health, Dr. Brennan was Chief Medical Officer of Aetna Inc.  In a previous academic career, he was Professor of Medicine at Harvard Medical School, and Professor of Law and Public Health at Harvard School of Public Health.

Ritesh is Chief Digital Officer for Ogilvy in the Health & Wellness practice.

He is responsible for providing digital vision, leadership and guidance for our Health & Wellness customers globally.

He joins Ogilvy after 4 years as the Chief Digital officer at Ogilvy CommonHealth, the specialist healthcare agency within WPP where, working with the creative and planning groups, Ritesh and his team provided digital strategy, technology development and innovation services, via the Ogilvy Digital Health Lab, to bring client campaigns to life for the digital world.

During his tenure, Ritesh and his team have created many new innovations for clients, from EHR Strategy, to the use of A/R, V/R Chat Bots and voice activated systems for marketers.
Prior to joining Ogilvy CommonHealth, Ritesh spent 5 years as the Global Head of Digital & Innovation at inVentiv Health where he worked on a number of projects on the clinical side of the business as well as the commercial side. In clinical, Ritesh worked to digitize the CRO and create digital patient recruiting solutions. In the commercial group, Ritesh worked on many the highly successful campaigns, including work for Allergan for Botox,, Latisse and Lapband, as well as Drive4copd to raise awareness of COPD. He and his team also pioneered the use of Social Media in Pharma marketing for clients in 2011, winning a Clio award for a campaign for Cystic Fibrosis using Facebook and Twitter.

He joined InVentiv after a stint as the SVP and Managing Director of HealthEd Digital—the digital arm of the HealthEd Group, a patient education agency based in Clark, New Jersey. There he worked on a number of digital projects, including branded and unbranded patient education sites.
Ritesh joined HealthEd after working at Cushman & Wakefield, a global real estate services company, where he was responsible for rolling out a global CRM solution for the company.
Ritesh has also been involved in several startups in his career. Most recently, he was the cofounder of Avivocom. As the CTO, Ritesh created a technology that uses a combination of video, VoIP and text chat to allow clients to converse with online prospects through banner ads. It is now widely used by IBM, Verizon, Intel, Adobe and other large corporations.

Ritesh co-founded Avivocom after working at Euro RSCG, where he was the Global CIO. He was responsible for Information Technology Strategy and Operations for the fifth-largest advertising and media company in the world. Ritesh joined Euro RSCG after four and a half years as the Vice President of Technology for Agency.com in New York, where he managed a global team of professionals creating the technical infrastructures for web-based applications.

Lori Melichar, a labor economist, is a director at the Foundation where she focuses on discovering, exploring and learning from cutting edge ideas with the potential to help create a Culture of Health. She is also the host of the Foundation’s Pioneering Ideas podcast.

Previously at the Foundation, Melichar managed several programs to focus a broad research community on studies to improve health and health care policy and practice, and was a key driver of efforts to advance the science of quality improvement (QI) research and evaluation.

Prior to joining the Foundation in 2002, she served with the National Institutes of Child Health and Development and the Demography of Inequality initiative at the University of Maryland Center on Population, Gender and Inequality. Melichar also worked at Pfizer Pharmaceuticals as a consultant and economic policy analyst and at the Project Hope Center for Health Affairs.

She holds a PhD and MA in economics from the University of Maryland at College Park and a BA in economics from Swarthmore College in Pennsylvania.

An Oklahoma native, Melichar resides in New York City with her husband and three children.

Dr. Paul Rothman is the Dean of the Medical Faculty for the Johns Hopkins University School of Medicine and Chief Executive Officer of Johns Hopkins Medicine, a $8 billion academic medical enterprise and a health system with a global reach. As Dean/CEO, Dr. Rothman oversees both the Johns Hopkins Health System and the School of Medicine. A rheumatologist and molecular immunologist, he came to Hopkins in July 2012 after having served as Dean of the Carver College of Medicine at the University of Iowa and leader of its clinical practice plan since 2008. Previously, he served as Head of Internal Medicine at the University of Iowa, beginning in 2004, and prior to that as Vice Chairman for Research and Founding Director of the Division of Pulmonary, Allergy and Critical Care Medicine at Columbia University College of Physicians and Surgeons, where he joined the faculty in 1990.

A 1980 Phi Beta Kappa graduate of the Massachusetts Institute of Technology, Rothman received his Medical degree from Yale University in 1984, earning a place in the Alpha Omega Alpha Honor Medical Society. He then trained at Columbia-Presbyterian Medical Center in internal medicine and rheumatology and accepted a postdoctoral fellowship at Columbia University prior to joining its medical school faculty.

Rothman’s research focused on immune system molecules known as cytokines. Specifically, he investigated the role these molecules play in the normal development of blood cells, as well as the abnormal development of these blood cell that leads to leukemia. He also studied the role of cytokines in immune system responses to asthma and allergies. His work was consistently funded by the National Institutes of Health.

His honors include a James S. McDonnell Foundation Career Development Award, a Pfizer Scholars Award, a Pew Scholar Award, a Leukemia Society of America Scholar Award and the Pharmacia Allergy Research Foundation International Award in 1997. Dr. Rothman is a member of the National Academy of Medicine, the American Academy of Arts and Sciences, and the American Society for Clinical Investigation. He served as President of the Association of American Physicians and was elected as a Fellow of the American Association for the Advancement of Sciences. Dr. Rothman serves on the Board of Merck and Co.

Vivek Ramaswamy is founder and Chief Executive Officer of Roivant Sciences. The Roivant family of companies includes multiple wholly-owned or majority-owned biopharmaceutical subsidiaries, each focused on a different disease area. With its affiliates, Roivant has raised over $2.8 billion in capital to date to fund clinical programs and pursue adjacent business opportunities in healthcare.

Prior to founding Roivant, Mr. Ramaswamy was an investor in the biotechnology sector. He currently serves as a member of the board of directors of Roivant Sciences and as chairman of the boards of directors of Axovant Sciences, Myovant Sciences, and Arbutus Biopharma Corporation. He received an A.B. summa cum laude in biology from Harvard College and a J.D. from Yale Law School.

Kenneth Stein, MD, FACC, FHRS, is currently Senior Vice President and Chief Medical Officer for Rhythm Management and Global Health Policy at Boston Scientific. Ken is a Phi Beta Kappa graduate of Harvard College (in Economics), and earned his MD from New York University School of Medicine. He completed his medical internship and residency at The New York-Presbyterian Hospital/Weill Cornell Medical Center, where he also completed his cardiology and cardiac electrophysiology training.

Prior to joining Boston Scientific in 2009, Dr. Stein held the position of Associate Director of Clinical Cardiac Electrophysiology at Weill Cornell Medical Center and Associate Professor of Medicine at Cornell University where he was widely published, authoring over 125 peer-reviewed scientific publications in the areas of cardiac electrophysiology with special interest in cardiac resynchronization therapy and risk stratification for sudden cardiac arrest. Dr. Stein currently oversees the clinical trials, medical safety, and medical education and clinical communications for Boston Scientific’s Cardiac Rhythm Management, Electrophysiology and Watchman Left Atrial Appendage Closure businesses as well as leading the corporate Global Health Policy team tasked with shaping the company’s policies with respect to global health care delivery and reimbursement.

Dr. Stein serves on the board of the Boston Scientific Political Action Committee and on the Scientific Advisory Board of Optum Labs. Since 2013, he has also served on the board of Childrens HeartLink, a registered 501c(3) nonprofit organization that trains and mentors medical teams in underserved parts of the world to diagnose and treat children with heart disease. Founded in 1969, Children’s HeartLink currently supports partner hospitals in Brazil, China, India, Malaysia, Ukraine and Vietnam.

Ramon Soto is Senior Vice President, Chief Marketing and Communications Officer, for Northwell Health, where he is responsible for the development and execution of Northwell’s brand strategy and all aspects of marketing and communications, including public relations, digital engagement, strategic and clinical marketing, internal communications and customer acquisition. Northwell Health is New York’s largest healthcare provider with 4 million patient visits per year in a network of 23 hospitals and 650 community, research and clinical facilities.

Ramon is the former chief marketing officer for Magellan Health, a healthcare services company, and previously was a senior vice president at Aetna, managing the global marketing function for Aetna’s commercial business.

Ramon received his B.A. from the State University of New York at Binghamton and his MBA from the Yale School of Management with a concentration in Healthcare. He serves on the Yale School of Management Alumni Board of Directors.

Imran is the founding partner at Action Potential Venture Capital, GSK’s corporate venture capital fund focused on investing in companies that pioneer bioelectronic medicines and their enabling technologies. Imran represents Action Potential as a board member in NeuSpera Medical, SetPoint Medical, Presidio Medical and Qionics. Prior to his role at Action Potential, Imran headed up GSK’s Investment Management group and was responsible for accessing technology and innovation external to GSK by making and managing investments in life science venture capital funds as limited partners and direct investments in biotechs. Imran has been with GSK for over 12 years, primarily in various business development functions leading and participating in in-licenses, out-licenses, research collaborations, co-development and co-promotion arrangements, equity investments, and M&A deals. Imran has trained as a Canadian Chartered Accountant and is based in Boston, MA.

Kelly graduated from Centenary College of New Jersey in 2012 earning her degree in English Literature and Secondary Education. While she is no longer in the classroom, she continues to be an advocate for educational equity for underprivileged students and believes that teachers should be at the center of education policy.

As a person that has battled Crohn’s disease for 16 years, she ended up in Amsterdam in 2017 to get a revolutionary new device called a Vagus Nerve Stimulator that put her into remission for the first time since diagnosis. Nowadays, she spends her days managing a shop in Montclair, NJ, freelance writing, designing curriculum, and advocating for the bioelectronic medicine that has saved her life.

As a previous luxury Hotel Executive, Mr. Gierlinger brings a unique perspective to the patient experience dialogue. However, it was his personal patient experience spending three months in hospitals that motivates him to challenge the status quo in healthcare. Now as Chief Experience Officer for Northwell Health, one of the largest Integrated Delivery Networks in the country, Mr. Gierlinger is driving culture transformation grounded in patient centeredness and empathy.

Mr. Gierlinger came to Northwell Health from the Henry Ford Health System in Detroit where he served as Vice President, Hospitality and Service Culture, responsible for creating a superior and consistent service experience for patients, visitors and employees. Mr. Gierlinger worked closely with leadership to drive culture change around improving the customer experience in every encounter across the system. Prior to that, he was an Administrator, Hospitality Services, for Henry Ford West Bloomfield Hospital, responsible for all aspects of non-clinical operations, the Wellness & Integrative Health Center, retail shops and café, and the customer experience. Additionally, he was an integral part of the team, leading the efforts to achieve the acclaimed Malcom Baldridge National Quality Award.

Mr. Gierlinger began his career in the luxury hotel business, holding a series of leadership positions with the Ritz-Carlton Hotel Company. He played a key role in the openings of several Ritz-Carlton hotels in Germany, Japan, Indonesia and the U.S., responsible for executing and implementing Ritz-Carlton service standards, training staff, and leading teams of trainers.

Mr. Gierlinger is an Executive Board member at The Beryl Institute and the Founding Council member of the Institute of Innovation.

He received a bachelor’s degree in hospitality business administration from the Bavaria Hotel Management Academy, Altoetting, Germany.

Elaine Brennan is one of the leaders of True North, a Northwell Health entity established to develop and invest in innovative products, technologies and services that will generate revenue to support the health system’s mission of delivering quality care, innovative research and education.
Ms. Brennan joined Northwell to create Pharma Ventures, a group tasked with establishing an innovative approach to managing and developing more collaborative and strategic relationships with the pharmaceutical industry.

Previously, Ms. Brennan was the CEO of Socrates, a health care information technology company, where she led the development and launch of its electronic health records system in the US. She also worked with Enterprise Ireland, managing the Irish life sciences companies entering the US market and founded also founded Gastroenterology Ireland, which combined a cluster of companies, research and development, and Irish opinion leaders in Ireland and the US.

Her pharmaceutical career at Roche, Bristol Myers Squibb and AbbVie included marketing/sales and clinical roles launching blockbuster products in the virology sector.
Ms. Brennan has published scientific articles on genetic engineering and biodegradable polymers applications, and patented many products in the same area. She earned her science degree in the United Kingdom and her early education in County Galway and Belgium.

Prof. Chad Bouton is the VP of Advanced Engineering and the Director of the Center for Bioelectronic Medicine at The Feinstein Institute for Medical Research, the research arm of the Northwell Health System in New York. Professor Bouton formerly served as research leader at Battelle Memorial Institute—the world’s largest independent research and development organization—where he spent 18 years researching and developing biomedical technology. At the Feinstein Institute, he is performing groundbreaking research in neurotechnology to treat paralysis and is developing new technologies to accelerate the field of bioelectronic medicine. Professor Bouton’s pioneering work, allowing a paralyzed person for the first time to regain movement using a brain implant, has been featured on 60 Minutes, CBS, and presented at TEDx. He holds over 70 patents worldwide and his technologies have been awarded three R&D 100 Awards and he was recognized by the US Congress for his work in the medical device field. He has been named Inventor of the Year and Distinguished Inventor by Battelle, and was selected by the National Academy of Engineering in 2011 to attend the Frontiers in Engineering Symposium.

Tyler Mathisen co-anchors CNBC’s “Power Lunch” (M-F, 1PM-3PM ET), one of the network’s longest running program franchises. He is also Vice President, Events Strategy for CNBC, working closely with the network’s events team to grow the rapidly expanding business.

Previously, Mathisen was co-anchor of “Nightly Business Report,” an award-winning evening business news program produced by CNBC for U.S. public television. In 2014, NBR was named best radio/TV show by the Society of American Business Editors and Writers (SABEW). Since joining CNBC in 1997, Mathisen has held a number of positions including managing editor of CNBC Business News, responsible for directing the network’s daily content and coverage. He was also co-anchor of CNBC’s “Closing Bell.”

Mathisen has reported one-hour documentaries for the network including “Best Buy: The Big Box Fights Back,” “Supermarkets Inc: Inside a $500 Billion Money Machine” and “Death: It’s a Living.” Mathisen was also host of the CNBC series “How I Made My Millions.”

Prior to CNBC, Mathisen spent 15 years as a writer, senior editor and top editor for Money magazine. Among other duties, he supervised the magazine’s mutual funds coverage, its annual investment forecast issue and its expansion into electronic journalism, for which it won the first-ever National Magazine Award for New Media in 1997.

In 1993, Mathisen won the American University-Investment Company Institute Award for Personal Finance Journalism for a televised series on “Caring for Aging Parents,” which aired on ABC’s “Good Morning America.” Mathisen served as money editor of “GMA” from 1991 to 1997. He also won an Emmy Award for a report on the 1987 stock market crash that aired on New York’s WCBS-TV.

A native of Arlington,Va., Mathisen graduated with distinction from the University of Virginia.

Dr. Tara Narula is a board certified cardiologist and is an Assistant Professor of Cardiovascular Medicine at the Zucker School of Medicine, Associate Director of the Cardiac Care Unit at Lenox Hill Hospital in Manhattan and a CBS News Medical Contributor. She contributes to various CBS News broadcasts and platforms including “CBS this Morning”, “CBS Evening News”, “CBSN” and “CBS Sunday Morning”. She is also a frequent contributor to O, Oprah Magazine. She joined Lenox Hill Heart & Vascular Institute of New York in 2010 and provides outpatient consultative care as well as inpatient cardiac critical care. She is additionally board certified in Nuclear Cardiology, Echocardiography and Internal Medicine. After graduating from Stanford University with degrees in Economics and Biology, she was founder and CEO of her own small business, Sun Juice Inc. Subsequently she obtained her medical degree at USC Keck School of Medicine where she graduated with Alpha Omega Alpha Society Honors. Dr. Narula completed her residency in internal medicine at Harvard University/Brigham and Women’s Hospital and her fellowship training in cardiology at New York Presbyterian-Weill Cornell Medical Center. Dr. Narula is currently a fellow of the American College of Cardiology (FACC). She serves as a member for both the NYC Go Red for Women Committee and is a national spokesperson for the AHA. She is a recipient of the Super Doctors Rising Star Award for NYC 2014 through 2018. Her interests include preventive cardiology, women’s health and the management of coronary artery disease.

Uwe Schoenbeck leads Pfizer’s External Science & Innovation (ES&I) team, which is responsible for enhancing Pfizer’s Worldwide R&D pre-clinical and clinical pipeline by introducing novel targets, prosecuting externally sourced cutting edge science through partnership with academia, and harnessing innovative assets and breakthrough technologies through partnerships with Biotech and Pharma.

ES&I is composed of three key pillars: a global External Search & Evaluation and Venture Investment team working across Pfizer’s therapeutic priority areas and sourcing transformative assets and technologies via scouting, seed funding, and NewCo formation; a team focused on novel target and biology discovery research to help drive rejuvenation of the pipeline and enhance Confidence in Rational in our programs; and the Centers for Therapeutic Innovation (CTI), a global externally-networked academic partnership for drug co-development. This end-to-end innovation capability aims to strengthen Pfizer’s research engine and be a key driver of a pipeline of truly differentiated first-in-class pipeline assets as well as breakthrough technologies by effectively combining external innovation with Pfizer’s internal drug development capabilities.

Dr. Schoenbeck brings fifteen years of pharmaceutical drug development experience to Pfizer’s R&D executive leadership team and Senior Leadership Committee. Prior to joining the company, he served as Vice President, Cardiovascular Research for Boehringer Ingelheim. Before joining industry, he held an Assistant Professor of Medicine position with Brigham & Women’s Hospital, Harvard Medical School. Uwe has served as a reviewer for multiple peer-reviewed journals and has published more than 100 peer-reviewed articles, review articles/book chapters and abstracts with particular contributions in molecular & cell biology, cardiovascular research, immunology, and metabolism.

Thomas is the head of health care investing at Qualcomm Ventures where he focuses on digital health care companies. Thomas is also a General Partner at dRx Capital, which is a joint venture investment company launched by Novartis and Qualcomm with a capital commitment up to $100M. As part of these roles, Thomas strives to catalyze the success of digital medicine products, services and business models by investing in high-growth, technology companies.

Prior to Qualcomm Ventures, Thomas was an investment professional at Providence Ventures, the venture capital arm at one of the nation’s leading healthcare delivery networks, Providence St. Joseph Health. Prior to Providence Ventures, Thomas was part of the strategic finance / strategic investing team at Cambia Health Solutions, the private equity sponsor for Regence Blue Cross Blue Shield, a nationally recognized health insurer committed to transforming healthcare. As part of his role at Cambia, Thomas had an observer seat on the Fund Management Team (FMT), the formal governing body established by the company to approve all VC, PE and M&A deals. Thomas was also a direct investment professional at Adams Street Partners where he supported the partnership on venture capital and growth equity opportunities.

Thomas holds his Master of Science in Medical Informatics and a Bachelor of Science in Biomedical Engineering from Northwestern University where he is a published author in the Journal of Surgical Oncology.

Chef Bruno Tison is the VP of Food Services and Corporate Chef within the Office of Patient & Customer Experience. Committed to delivering a world-class food experience for our patients, and building a healthy workplace for employees, Chef Tison is responsible for promoting consistency and elevating the quality of food and beverage throughout the organization.

As a 30+ year hospitality industry veteran that includes Executive Chef of the legendary Plaza Hotel in New York City, Chef Tison’s nouvelle cuisine has earned extensive critical acclaim. Tison comes to Northwell from the Fairmont Sonoma Mission Inn and Spa in California – a Condé Nast “Top Ten” rated Spa & Resort. There he successfully led the team in receiving the celebrated Michelin Star recognition for three consecutive years.

Prior to joining the Plaza Hotel, Chef Tison trained with several of France’s legendary master chefs. Under their tutelage, Tison developed and refined his own unique style. He also worked in some of America’s most prestigious kitchens such as Beau Geste, in New York City, Ernie’s Restaurant and Pierre at Le Meridien, in San Francisco.

A native of northern France, Chef Tison began his culinary education at Belgium’s prestigious Institut Technique Des Metiers De L’Alimentation, where he graduated with highest honors and was awarded first prize for excellence in culinary achievement. Chef Tison is also a member of the Société Culinaire Philantropique in New York City.

His immense passion for healthy foods along with an extensive breadth of experience drives Chef Tison to make an impactful difference within the healthcare environment.

Dr. Chernoff is a molecular diagnostics and biopharmaceutical industry veteran who has played pivotal roles in moving early stage R&D programs successfully through clinical development and product commercialization and evaluating a broad range of in-licensing opportunities. He oversees all clinical development activities for SetPoint as the company continues to advance its bioelectronic medicine platform, reporting to Anthony Arnold, Chief Executive Officer of SetPoint Medical.

Prior to joining SetPoint, Dr. Chernoff has served as a translational medicine consultant to more than 40 biotechnology, pharmaceutical and medical device companies and has held chief medical officer posts with a number of companies, including Crescendo Bioscience, Adamas Pharma, XDX, CardioDX, Tethys Biosciences and Aquinox Pharma. Dr. Chernoff was Vice President of Corporate Technology at Elan Pharmaceuticals and Medical Director at Chiron Diagnostics, where he played a pivotal role in the development of viral load assays for HIV, HCV, HBV and CMV. He was a principal with life sciences management consulting firm Keelin Reeds Ventures and entrepreneur in residence and operating partner at TPG Biotech VC Fund. He received a Bachelor of Science degree in molecular biology from Yale University and an MD from New York University and completed his medical training and research in internal medicine, rheumatology and infectious disease at the University of California San Francisco Medical Center. He also served as Chief Resident in Internal Medicine at San Francisco General Hospital and Assistant Chief of Medicine at UCSF Medical Center.

Mike leads business development and partnerships for Google Brain. His charter includes working with large healthcare systems to move research ideas into translational research/products and partnerships. During his tenure at Google he has also led business development at Google [X]/Google Life Sciences, was part of the early founding group to create Google Capital – Google’s private equity investment vehicle, led the creation of the Google Play Store for Android products, and led acquisitions and investments within the Corporate Development Group. Prior to working at Google, Mike held positions at McCown DeLeeuw and Goldman Sachs. Mike received his MBA from Harvard Business School and a Bachelors at Emory University in Economics & Italian studies.

Shyam focuses on corporate strategy development at Avanos, a Medical Devices company. Shyam has responsibility for technology M&A and strategic alliances. Shyam joined the corporate development team at Kimberly-Clark Corp., where led various New Business Development initiatives before transitioning into Avanos as part of the spin-off of the Kimberly-Clark healthcare. Prior to joining Kimberly-Clark, Shyam was a group leader within the pharmaceutical R&D group at Abbott Labs, now AbbVie. At Abbott, Shyam led various API development projects. Shyam received his Ph.D. in chemistry from the University of Toledo and an MBA from the University of Chicago.

Matthew Herper covers science and medicine for Forbes Media.

He believes this is biology’s century. He has covered science and medicine for Forbes from the Human Genome Project through Vioxx to the blossoming DNA technology changing the world today.

Sree Sreenivasan is a leading social and digital media consultant and trainer, working with nonprofits, startups, companies and executives around the world. He has served as Chief Digital Officer of New York City, the Metropolitan Museum of Art and Columbia University (where he was a full-time professor of journalism for 20+ years). He is in the midst of a 25-city, 10-country workshop tour. In 2015, he was named to Fast Company’s list of Most Creative People in Business.

As Senior Vice President of Northwell Ventures, Tom Thornton is responsible for identifying and fostering innovative ideas that enhance the growth of the health system’s clinical and nonclinical enterprises.

In this role, he works with senior leadership to develop and advance clinical and nonclinical ideas, bringing them into practice and the market and building strategic partnerships and relationships within the broader regional ecosystem. Mr. Thornton manages all the Northwell innovation programs, including technology commercialization, enterprise growth and investment management.

Prior to Northwell, Mr. Thornton led the Healthcare Innovation Alliance at Cleveland Clinic Innovations, a program aimed at forming multi-institutional collaborations to foster and accelerate the commercialization of medical innovations.